Robert Dreicer, MD, discusses the clinical implications of the phase 3 JAVELIN Bladder 100 trial in locally advanced or metastatic urothelial cancer.
Robert Dreicer, MD, deputy director, director of solid tumor oncology, Division of Hematology/Oncology, University of Virginia Cancer Center, discusses the clinical implications of the phase 3 JAVELIN Bladder 100 trial (NCT02603432) in locally advanced or metastatic urothelial cancer.
Findings from the JAVELIN Bladder 100 trial demonstrated that first-line maintenance therapy with avelumab (Bavencio) plus best supportive care significantly prolonged overall survival vs best supportive care alone in patients with advanced urothelial carcinoma that had not progressed on first-line platinum-based chemotherapy.
Despite increased research efforts with checkpoint inhibitors and other novel therapies in recent years, survival remains poor for patients with urothelial carcinoma, Dreicer says. The results of the JAVELIN Bladder 100 trial were significant for this patient population because maintenance avelumab conferred clinical benefit vs best supportive care to patients irrespective of prior carboplatin or cisplatin chemotherapy as long as they obtained at least stable disease, Dreicer explains.
The results furthered the clinical management of urothelial carcinoma and added a new standard of care for patients, Dreicer concludes.